Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 5/20 | 0.42 |
| ▸ | ACHE | P22303 | 5/20 | 0.42 |
| ▸ | BACE1 | P56817 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4332775 | 1.00 | DRD4 (0.48) | DRD4DRD3HTR1AHTR2ASLC6A4 | |
| SCHEMBL4331292 | 0.91 | DRD4 (0.46) | DRD4DRD3HTR1AHTR2ASLC6A4 | |
| SCHEMBL4331295 | 0.91 | DRD4 (0.46) | DRD4DRD3HTR1AHTR2ASLC6A4 | |
| SCHEMBL4328501 | 0.91 | AURKA (0.49) | DRD4DRD3HTR1AHTR2ASLC6A4 | |
| SCHEMBL4328497 | 0.91 | AURKA (0.49) | DRD4DRD3HTR1AHTR2ASLC6A4 | |
| SCHEMBL4323752 | 0.84 | MAOA (0.43) | RETKDM4EMAOA | |
| SCHEMBL4323750 | 0.84 | MAOA (0.43) | RETKDM4EMAOA | |
| SCHEMBL4336145 | 0.83 | RET (0.45) | RETBCHEACHEBACE1KDM4E | |
| SCHEMBL4344729 | 0.83 | MAOB (0.47) | DRD4DRD3HTR1AHTR2ASLC6A4 | |
| SCHEMBL4336141 | 0.83 | RET (0.45) | RETBCHEACHEBACE1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7521062-B2 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20050069555-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | MAVS, IRF3, HAVCR2 | DRD4 3597/4885DRD3 3208/4885HTR1A 4305/4885 |
| US-20050069555-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | MAVS, IRF3, HAVCR2 | DRD4 3150/4885DRD3 3120/4885HTR1A 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.